Pteisolic acid G, a novel ent‑kaurane diterpenoid, inhibits viability and induces apoptosis in human colorectal carcinoma cells
Author(s) -
Shuangli Qiu,
Xin Wu,
Hongbo Liao,
Xiaobin Zeng,
Senwang Zhang,
Xiaofen Lu,
Xiaohong He,
XiaoQi Zhang,
WenCai Ye,
Hua Wu,
Xiaohui Zhu
Publication year - 2017
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2017.6889
Subject(s) - dishevelled , apoptosis , wnt signaling pathway , viability assay , gsk 3 , cell cycle , biology , oncogene , cancer research , western blot , cancer cell , chemistry , cancer , signal transduction , microbiology and biotechnology , biochemistry , frizzled , genetics , gene
Human colorectal cancer (CRC) is a major cause of cancer morbidity and mortality, and its incidence rates are increasing in economical transitioning areas globally. To develop efficient chemotherapy drugs for CRC, the present study isolated and identified a novel ent -kaurane diterpenoid from Pteris semipinnata , termed pterisolic acid G (PAG). This ent -kaurane diterpenoid was demonstrated to significantly inhibit the growth of human CRC HCT116 cells in a time- and dose-dependent manner, determined using the Cell Counting Kit-8 assay. Additionally, western blot analysis, Hoechst 33342 staining and cytometry analysis revealed that PAG not only inhibited the viability of HCT116 cells by suppressing the dishevelled segment polarity protein 2/glycogen synthase kinase 3 β/β-catenin pathway, but also induced the apoptosis of HCT116 cells by downregulating nuclear factor-κB p65 activity, stimulating p53 expression and promoting the generation of intracellular reactive oxygen species. These results suggest that PAG, a novel inhibitor of the Wnt/β-catenin pathway and inducer of apoptosis, should be investigated in more detail using in vivo experiments and comprehensive mechanistic studies in order to examine the potential use of PAG as a novel therapeutic agent for the treatment of CRC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom